The high expression of CDKN2A can promote the proliferation of cancer cells, inhibit the apoptosis of cancer cells, induce tumor interstitial angiogenesis, reduce the sensitivity of cancer cells to chemoradiotherapy, and ultimately affect the prognosis of HCC patients [35]. Here, CDKN2A is linked to neoplasm.